Toward the development of an effective simultaneous inhibition strategy of EGFR and MET activation in TMZ-resistant glioma, we looked for a rational design of nanoinhibitor simultaneously targeting EGFR and MET, and developed a nanoinhibitor, BIP-MPC-NP, which can simultaneously mitigate EGFR and MET activation by conjugating Inherbin326 (denoted as EGFR-binding peptide, EBP) and cMBP28,36 (denoted as MET-binding peptide, MBP) on the surface of NHS-PEG8-Mal modified MPC-NPs (Fig. 1b). The gene discussed is MBP; the disease is central nervous system cancer.